Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models
Hoa T.T. Ha, SiYi Liu, Xuan T.A. Nguyen, Linh K. Vo, Nancy C.P. Leong, Dat T. Nguyen, Shivaranjani Balamurugan, Pei Yen Lim, YaJun Wu, Eunju Seong, Toan Q. Nguyen, Jeongah Oh, Markus R. Wenk, Amaury Cazenave-Gassiot, Zuhal Yapici, Wei-Yi Ong, Margit Burmeister, Long N. Nguyen
Hoa T.T. Ha, SiYi Liu, Xuan T.A. Nguyen, Linh K. Vo, Nancy C.P. Leong, Dat T. Nguyen, Shivaranjani Balamurugan, Pei Yen Lim, YaJun Wu, Eunju Seong, Toan Q. Nguyen, Jeongah Oh, Markus R. Wenk, Amaury Cazenave-Gassiot, Zuhal Yapici, Wei-Yi Ong, Margit Burmeister, Long N. Nguyen
View: Text | PDF
Research Article Aging Metabolism

Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models

  • Text
  • PDF
Abstract

Accumulation of sphingolipids, especially sphingosines, in the lysosomes is a key driver of several lysosomal storage diseases. The transport mechanism for sphingolipids from the lysosome remains unclear. Here, we identified SPNS1, which shares the highest homology to SPNS2, a sphingosine-1-phosphate (S1P) transporter, functions as a transporter for lysolipids from the lysosome. We generated Spns1-KO cells and mice and employed lipidomic and metabolomic approaches to reveal SPNS1 ligand identity. Global KO of Spns1 caused embryonic lethality between E12.5 and E13.5 and an accumulation of sphingosine, lysophosphatidylcholines (LPC), and lysophosphatidylethanolamines (LPE) in the fetal livers. Similarly, metabolomic analysis of livers from postnatal Spns1-KO mice presented an accumulation of sphingosines and lysoglycerophospholipids including LPC and LPE. Subsequently, biochemical assays showed that SPNS1 is required for LPC and sphingosine release from lysosomes. The accumulation of these lysolipids in the lysosomes of Spns1-KO mice affected liver functions and altered the PI3K/AKT signaling pathway. Furthermore, we identified 3 human siblings with a homozygous variant in the SPNS1 gene. These patients suffer from developmental delay, neurological impairment, intellectual disability, and cerebellar hypoplasia. These results reveal a critical role of SPNS1 as a promiscuous lysolipid transporter in the lysosomes and link its physiological functions with lysosomal storage diseases.

Authors

Hoa T.T. Ha, SiYi Liu, Xuan T.A. Nguyen, Linh K. Vo, Nancy C.P. Leong, Dat T. Nguyen, Shivaranjani Balamurugan, Pei Yen Lim, YaJun Wu, Eunju Seong, Toan Q. Nguyen, Jeongah Oh, Markus R. Wenk, Amaury Cazenave-Gassiot, Zuhal Yapici, Wei-Yi Ong, Margit Burmeister, Long N. Nguyen

×

Figure 1

SPNS1 is a putative lysosomal transporter that is required for survival in mice.

Options: View larger image (or click on image) Download as PowerPoint
SPNS1 is a putative lysosomal transporter that is required for survival ...
(A) Localization of SPNS1 in HEK293 cells. Human SPNS1 cDNA was cotransfected with LAMP1-RFP. Spns1 was colocalized with lysosomal marker LAMP1. (B) Representative images of E12.5 and E13.5 of WT, heterozygous (HET), and global Spns1 KO (KO) embryos. Arrows show maldevelopment of the eyes. (C) gSpns1-KO embryos were smaller than WT and HET controls. Each symbol represents 1 embryo (1-way ANOVA; n = 16 for WT, n = 22 for HET, n = 8 for KO; **P < 0.01; data are expressed as mean ± SD). (D) Gross anatomy of a control and gSpns1-KO embryos at E13.5. (E) Representative immunostaining with GLUT1 of the brain vasculature of controls and gSpns1-KO embryos. (F) Quantification of blood vessel density in the brain of control and gSpns1-KO embryos at E13.5. Each symbol represents 1 embryo (2-tailed unpaired t test; n = 4; *P < 0.05; data are expressed as mean ± SD). (G) Quantification of expression of GLUT1 in neocortical regions of gSpns1-KO embryos was significantly reduced. Each symbol represents 1 embryo (2-tailed unpaired t test; n = 4; **P < 0.01; data are expressed as mean ± SD). (H) Cortical thickness of gSpns1-KO embryos was reduced. Each symbol represents 1 embryo. n = 4 for each genotype. (I) Transmission electron microscopic images of brain sections of E12.5 WT and gSpns1-KO embryos. Accumulation of membranous structures (demarcated area) in the cytoplasm of brain cells of gSpns1-KO embryos. M, mitochondria. n = 3 per genotype.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts